ACAD
Acadia Pharmaceuticals Inc
A biopharmaceutical company that develops and sells medicines for brain and nervous-system conditions. Its drug NUPLAZID was the first FDA-approved treatment for the hallucinations and delusions that can accompany Parkinson's disease, and its DAYBUE is the first and only approved therapy for Rett syndrome, a rare genetic disorder. Acadia began in 1993 as a small Vermont lab called Receptor Technologies, then took its name from Acadia National Park when it moved to San Diego. It originally set out to treat Parkinson's symptoms, but an early twist of fate redirected the science toward tackling hallucinations instead.
CUSIP: 004225108HealthcareUS1 holder
Total Value
$1.27M
Total Shares
50.3K
Net Share Change
-91.5K
Activity
1 selling
Investor
Value
Shares
Weight
Change
